Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen V Liu

Showing results (91-100 of 187) with videos related to

Pageof 19
Sort By:
Lung Cancer (Amsterdam, Netherlands)|February 23, 2025
Corrigendum to "Real-world treatment sequencing and effectiveness of second- and third-generation ALK tyrosine kinase inhibitors for ALK-positive advanced non-small cell lung cancer" [Lung Cancer 195 (2024) 107919]Jessica R Bauman, Geoffrey Liu, Isabel Preeshagul, et al.
Journal for Immunotherapy of Cancer|February 18, 2021
Real-world survival outcomes with immune checkpoint inhibitors in large-cell neuroendocrine tumors of lungElizabeth Dudnik, Samuel Kareff, Mor Moskovitz, et al.
Cancers|September 13, 2025
Prognostic Significance and Emerging Predictive Potential of Interleukin-1β Expression in Oncogene-Driven NSCLCMengni Guo, Won Jin Jeon, Bowon Joung, et al.
Lung Cancer (Amsterdam, Netherlands)|August 28, 2024
Real-world treatment sequencing and effectiveness of second- and third-generation ALK tyrosine kinase inhibitors for ALK-positive advanced non-small cell lung cancerJessica R Bauman, Geoffrey Liu, Isabel Preeshagul, et al.
Lung Cancer (Amsterdam, Netherlands)|November 2, 2024
Corrigendum to "Real-world treatment sequencing and effectiveness of second- and third-generation ALK tyrosine kinase inhibitors for ALK -positive advanced non-small cell lung cancer" [Lung Cancer 195 (2024) 107919]Jessica R Bauman, Geoffrey Liu, Isabel Preeshagul, et al.
Clinical Genitourinary Cancer|July 3, 2017
A Phase II Trial of AEZS-108 in Castration- and Taxane-Resistant Prostate CancerSteven S Yu, Kanthi Athreya, Stephen V Liu, et al.
Clinical Lung Cancer|January 3, 2025
Phase II Parallel Arm Study of Sacituzumab Govitecan-Hziy in Patients With Advanced Thymoma or Thymic CarcinomaJennifer A Marks, Jaeil Ahn, Joshua E Reuss, et al.
Journal for Immunotherapy of Cancer|December 19, 2019
Safety and efficacy of immune checkpoint inhibitors (ICIs) in cancer patients with HIV, hepatitis B, or hepatitis C viral infectionNeil J Shah, Ghassan Al-Shbool, Matthew Blackburn, et al.
JTO Clinical and Research Reports|September 30, 2021
Identification of Novel <i>CDH1-NRG2</i>α and <i>F11R-NRG2α</i> Fusions in NSCLC Plus Additional Novel <i>NRG2α</i> Fusions in Other Solid Tumors by Whole Transcriptome SequencingSai-Hong Ignatius Ou, Joanne Xiu, Misako Nagasaka, et al.
Clinical Lung Cancer|October 9, 2024
Use of Oncogene Overlap by Tissue-Based Next-Generation Sequencing to Explore the Mutational Landscape and Survival Impact of HER2, KRAS and MET Copy-Number Gain in Nonsmall Cell Lung CancerAlexander S Watson, Harris B Krause, Andrew Elliott, et al.
Pageof 19

Showing results (91-100 of 187) with videos related to

Sort By:
Pageof 19
Lung Cancer (Amsterdam, Netherlands)|February 23, 2025
Corrigendum to "Real-world treatment sequencing and effectiveness of second- and third-generation ALK tyrosine kinase inhibitors for ALK-positive advanced non-small cell lung cancer" [Lung Cancer 195 (2024) 107919]Jessica R Bauman, Geoffrey Liu, Isabel Preeshagul, et al.
Journal for Immunotherapy of Cancer|February 18, 2021
Real-world survival outcomes with immune checkpoint inhibitors in large-cell neuroendocrine tumors of lungElizabeth Dudnik, Samuel Kareff, Mor Moskovitz, et al.
Cancers|September 13, 2025
Prognostic Significance and Emerging Predictive Potential of Interleukin-1β Expression in Oncogene-Driven NSCLCMengni Guo, Won Jin Jeon, Bowon Joung, et al.
Lung Cancer (Amsterdam, Netherlands)|August 28, 2024
Real-world treatment sequencing and effectiveness of second- and third-generation ALK tyrosine kinase inhibitors for ALK-positive advanced non-small cell lung cancerJessica R Bauman, Geoffrey Liu, Isabel Preeshagul, et al.
Lung Cancer (Amsterdam, Netherlands)|November 2, 2024
Corrigendum to "Real-world treatment sequencing and effectiveness of second- and third-generation ALK tyrosine kinase inhibitors for ALK -positive advanced non-small cell lung cancer" [Lung Cancer 195 (2024) 107919]Jessica R Bauman, Geoffrey Liu, Isabel Preeshagul, et al.
Clinical Genitourinary Cancer|July 3, 2017
A Phase II Trial of AEZS-108 in Castration- and Taxane-Resistant Prostate CancerSteven S Yu, Kanthi Athreya, Stephen V Liu, et al.
Clinical Lung Cancer|January 3, 2025
Phase II Parallel Arm Study of Sacituzumab Govitecan-Hziy in Patients With Advanced Thymoma or Thymic CarcinomaJennifer A Marks, Jaeil Ahn, Joshua E Reuss, et al.
Journal for Immunotherapy of Cancer|December 19, 2019
Safety and efficacy of immune checkpoint inhibitors (ICIs) in cancer patients with HIV, hepatitis B, or hepatitis C viral infectionNeil J Shah, Ghassan Al-Shbool, Matthew Blackburn, et al.
JTO Clinical and Research Reports|September 30, 2021
Identification of Novel <i>CDH1-NRG2</i>α and <i>F11R-NRG2α</i> Fusions in NSCLC Plus Additional Novel <i>NRG2α</i> Fusions in Other Solid Tumors by Whole Transcriptome SequencingSai-Hong Ignatius Ou, Joanne Xiu, Misako Nagasaka, et al.
Clinical Lung Cancer|October 9, 2024
Use of Oncogene Overlap by Tissue-Based Next-Generation Sequencing to Explore the Mutational Landscape and Survival Impact of HER2, KRAS and MET Copy-Number Gain in Nonsmall Cell Lung CancerAlexander S Watson, Harris B Krause, Andrew Elliott, et al.
Pageof 19